- Home
- VYGR
as 02-21-2025 4:00pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 235.4M | IPO Year: | 2015 |
| Target Price: | $15.53 | AVG Volume (30 days): | 374.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | -62.72 |
| 52 Week Low/High: | $4.00 - $10.66 | Next Earning Date: | 03-03-2025 |
| Revenue: | $163,784,000 | Revenue Growth: | 3.40% |
| Revenue Growth (this year): | -63.16% | Revenue Growth (next year): | -24.43% |
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sandrock Alfred | VYGR | President & CEO | Feb 11 '25 | Sell | $4.45 | 16,644 | $74,065.80 | 308,518 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 11 '25 | Sell | $4.45 | 5,413 | $24,087.85 | 81,023 | |
| Swartz Robin | VYGR | COO & CBO | Jan 14 '25 | Sell | $5.09 | 3,087 | $15,712.83 | 109,241 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Jan 14 '25 | Sell | $5.13 | 1,191 | $6,109.83 | 81,023 | |
| Swartz Robin | VYGR | COO&CBO | Dec 23 '24 | Sell | $5.65 | 6,500 | $36,725.00 | 109,241 |
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
Insider Monkey
10 days ago
Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now
MT Newswires
11 days ago
Wedbush Adjusts Price Target on Voyager Therapeutics to $9 From $11, Maintains Outperform Rating
MT Newswires
11 days ago
Voyager Therapeutics Shares Fall After Dropping Plan for VY9323 IND Filing in Mid-2025
GlobeNewswire
11 days ago
Voyager Provides Update on SOD1 ALS Gene Therapy Program
GlobeNewswire
16 days ago
Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference
Zacks
23 days ago
What Makes Voyager Therapeutics (VYGR) a New Buy Stock
MT Newswires
a month ago
Cantor Fitzgerald Initiates Voyager Therapeutics at Overweight
Insider Monkey
2 months ago
Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?
Compare VYGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.